Merck KGaA
MKKGYDrugs in Pipeline
11
Phase 3 Programs
7
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 0 past
No catalysts found.
Saizen®
Idiopathic Short Stature
RNF
Multiple Sclerosis
Cisplatin
Squamous Cell Carcinoma of the Head and Neck
GONAL-f®
Infertility
F0434
Diabetic Neuropathies
MSJ-0011
Anovulation
Cetuximab
Neoplasm Metastasis
Tepotinib
Carcinoma, Hepatocellular
Emfilermin, recombinant human leukemia inhibitory factor (r-hLIF)
Infertility Implantation Failure
Cisplatin/Carboplatin
Squamous Cell Carcinoma of the Head and Neck
Tecemotide (L-BLP25)
Non-small Cell Lung Cancer
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Saizen® | Phase 3 | Idiopathic Short Stature | - | - |
RNF | Phase 3 | Multiple Sclerosis | - | - |
Cisplatin | Phase 3 | Squamous Cell Carcinoma of the Head and Neck | - | - |
GONAL-f® | Phase 3 | Infertility | - | - |
F0434 | Phase 3 | Diabetic Neuropathies | - | - |
MSJ-0011 | Phase 3 | Anovulation | - | - |
Cetuximab | Phase 3 | Neoplasm Metastasis | - | - |
Tepotinib | Phase 2 | Carcinoma, Hepatocellular | - | - |
Emfilermin, recombinant human leukemia inhibitory factor (r-hLIF) | Phase 2 | Infertility Implantation Failure | - | - |
Cisplatin/Carboplatin | Phase 2 | Squamous Cell Carcinoma of the Head and Neck | - | - |
Tecemotide (L-BLP25) | Phase 2 | Non-small Cell Lung Cancer | - | - |
Frequently asked questions
What is in Merck KGaA's drug pipeline?→
CatalystAlert tracks 11 drug candidates in Merck KGaA's (MKKGY) pipeline across Phase 3, Phase 2. Its lead program is Saizen® (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Merck KGaA's next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Merck KGaA (MKKGY) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track MKKGY biotech catalysts?→
Add MKKGY to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Merck KGaA's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.